GH Receptor Antagonist: Mechanism of Action and Clinical Utility

被引：0
|
作者：
Sowmya K. Surya
Ariel L. Barkan
机构：
[1] University of Michigan Hospitals,Division of Endocrinology
来源：
Reviews in Endocrine and Metabolic Disorders | 2005年 / 6卷
关键词：
acromegaly; GH receptor antagonists; Pegvisomant;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
This review focuses on the development of GH receptor antagonist as a novel agent for treatment of acromegaly, its mechanism of action and potential areas of use. A brief overview of acromegaly, its diagnosis and existing medical, surgical and radiotherapy options of treatment is necessary to justify the addition of yet another therapeutic modality to the already vast therapeutic armamentarium.
引用
收藏
页码：5 / 13
页数：8
相关论文
共 50 条
  • [31] On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039
    Palucha-Poniewiera, Agnieszka
    Wieronska, Joanna M.
    Branski, Piotr
    Stachowicz, Katarzyna
    Chaki, Shigeyuki
    Pilc, Andrzej
    PSYCHOPHARMACOLOGY, 2010, 212 (04) : 523 - 535
  • [32] PITUITARY RECEPTOR-SITE BLOCKADE BY A GONADOTROPIN-RELEASING HORMONE ANTAGONIST INVIVO - MECHANISM OF ACTION
    HEBER, D
    DODSON, R
    SWERDLOFF, RS
    CHANNABASAVAIAH, K
    STEWART, JM
    SCIENCE, 1982, 216 (4544) : 420 - 421
  • [33] On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039
    Agnieszka Pałucha-Poniewiera
    Joanna M. Wierońska
    Piotr Brański
    Katarzyna Stachowicz
    Shigeyuki Chaki
    Andrzej Pilc
    Psychopharmacology, 2010, 212 : 523 - 535
  • [34] Evidence for growth hormone (GH) autoregulation in pituitary somatotrophs in GH antagonist-transgenic mice and GH receptor-deficient mice
    Asa, SL
    Coschigano, KT
    Bellush, L
    Kopchick, JJ
    Ezzat, S
    AMERICAN JOURNAL OF PATHOLOGY, 2000, 156 (03): : 1009 - 1015
  • [35] Use of a GH receptor antagonist (GHRA) to explore the relationship between GH and IGF-I in adults with severe GH deficiency (GHD)
    Berg, C. A.
    Pokrajac, A.
    Bidlingmaier, M.
    Strasburger, C. J.
    Shalet, S. M.
    Trainer, P. J.
    CLINICAL ENDOCRINOLOGY, 2009, 70 (03) : 439 - 445
  • [36] Reduction of Growth Hormone (GH) Action in GH Antagonist Mice Results in a Dwarf and Obese Phenotype with Impaired Glucose Metabolism
    Householder, Lara A.
    Suer, Ozan Yigit
    Funk, Kevin Ray
    Black, Kathleen
    Kowalski, Jesse
    Lesende, Vivian
    List, Edward O.
    Kopchick, John J.
    Berryman, Darlene E.
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [37] USE OF THE RECOMBINANT GH RECEPTOR ANTAGONIST PEGVISOMANT (PGV) IN ACROMEGALY: EFFICACY AND SAFETY
    Garcia-Arnes, J.
    Gonzalez-Molero, I.
    Dominguez-Lopez, M.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 63 - 63
  • [38] A case of an acromegalic patient resistant to the recommended maximum GH receptor antagonist dosage
    Dimopoulou, C.
    Sievers, C.
    Bidlingmaier, M.
    Stalla, G. K.
    HIPPOKRATIA, 2012, 16 (01) : 80 - 82
  • [39] Clinical utility of serum Interleukin-1 receptor antagonist levels as a diagnostic and prognostic assay in surgical patients
    Shailendra Kapoor
    Langenbeck's Archives of Surgery, 2009, 394 : 401 - 402
  • [40] Clinical utility of serum Interleukin-1 receptor antagonist levels as a diagnostic and prognostic assay in surgical patients
    Kapoor, Shailendra
    LANGENBECKS ARCHIVES OF SURGERY, 2009, 394 (02) : 401 - 402
12345